{"created":"2023-06-19T10:43:55.173505+00:00","id":4269,"links":{},"metadata":{"_buckets":{"deposit":"2dfb9ba6-0129-4cfe-a110-398e5d32f6e6"},"_deposit":{"created_by":11,"id":"4269","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"4269"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00004269","sets":["10:37"]},"author_link":[],"item_6_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-01-31","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageStart":"120","bibliographicVolumeNumber":"18","bibliographic_titles":[{"bibliographic_title":"BMC Cancer","bibliographic_titleLang":"en"}]}]},"item_6_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"松本, 寛史","creatorNameLang":"ja"}]}]},"item_6_date_granted_70":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2022-03-10"}]},"item_6_degree_grantor_68":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"滋賀医科大学"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"14202","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_6_degree_name_67":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_6_description_14":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"pdf","subitem_description_type":"Other"}]},"item_6_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background:\nRamucirumab has recently proved to be effective for advanced or recurrent gastric cancer (AGC). Ascites and peritoneal metastasis are among the most common complications of AGC. However, there are few data on the safety and efficacy of paclitaxel plus ramucirumab in patients with AGC with ascites. The purpose of this retrospective study was to evaluate the safety and efficacy of paclitaxel plus ramucirumab in patients with AGC with ascites. ","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Methods:\nWe retrospectively evaluated the safety and efficacy of paclitaxel plus ramucirumab in patients with AGC with ascites in comparison with patients without ascites in a single institution from June 2015 to May 2016. The median progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method, and differences evaluated using the Log-lank test. The differences in baseline characteristics and response rates of each ascites group were calculated for homogeneity by chi-square tests and for trends by Fisher's exact test. ","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Results:\nEighty-three patients were analyzed in this study. Ascites was detected in 40 patients, 26 patients (31%) had small to moderate ascites and 14 (17%) had massive ascites. The proportion of patients who started with a reduced dose of paclitaxel was higher for patients with massive ascites than others. The frequencies of any grade 3 or 4 hematological toxicity were 51% in patients without ascites, 77% in patients with small to moderate ascites, and 71% in patients with massive ascites. The frequencies of common ramucirumab-related adverse events were also not significantly different among ascites groups, however one patient had a tumor hemorrhage, and one patient had a gastrointestinal perforation. PFS and OS were shorter in patients with massive ascites than in patients with small or moderate ascites or patients without ascites. ","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Conclusions:\nThe use of paclitaxel and ramucirumab in patients with AGC with large amounts of ascites was tolerable with adequate dose modification. However, we should pay attention to the risks of ramucirumab-related toxicity in patients with bleeding tumors or intestinal stenosis. ","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_6_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Thesis or Dissertation","subitem_description_type":"Other"}]},"item_6_description_69":{"attribute_name":"学位授与年度","attribute_value_mlt":[{"subitem_description":"令和3年度","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_6_dissertation_number_71":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"乙第475号"}]},"item_6_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"BioMed Central","subitem_publisher_language":"en"}]},"item_6_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"29385993","subitem_relation_type_select":"PMID"}}]},"item_6_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.1186/s12885-018-4057-7"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1186/s12885-018-4057-7","subitem_relation_type_select":"DOI"}}]},"item_6_relation_48":{"attribute_name":"関係URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"博士論文要旨"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://hdl.handle.net/10422/00013354","subitem_relation_type_select":"HDL"}}]},"item_6_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© The Author(s). 2018"}]},"item_6_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1471-2407","subitem_source_identifier_type":"EISSN"}]},"item_6_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"MATSUMOTO, Hiroshi","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-06-16"}],"displaytype":"detail","filename":"s12885-018-4057-7.pdf","filesize":[{"value":"427.2 kB"}],"format":"application/pdf","licensefree":"This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org\n/licenses/by/4.0/), which permits unrestricted use, distribution, and\nreproduction in any medium, provided you give appropriate credit to \nthe original author(s) and the source, provide a link to the Creative \nCommons license, and indicate if changes were made. The Creative\nCommons Public Domain Dedication waiver \n(http://creativecommons.org/publicdomain/zero/1.0/) applies to the\ndata made available in this article, unless otherwise stated.","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"s12885-018-4057-7","objectType":"fulltext","url":"https://shiga-med.repo.nii.ac.jp/record/4269/files/s12885-018-4057-7.pdf"},"version_id":"8492a081-54f1-4add-99c6-0a4f69c4737d"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Gastric cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Ascites","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Progression-free survival","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Paclitaxel","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Ramucirumab","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites","subitem_title_language":"en"}]},"item_type_id":"6","owner":"11","path":["37"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2022-06-16"},"publish_date":"2022-06-16","publish_status":"0","recid":"4269","relation_version_is_last":true,"title":["A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites"],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-09-15T05:19:07.460802+00:00"}